See more : Tata Technologies Limited (TATATECH.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Poseida Therapeutics, Inc. (PSTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poseida Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Spirit Realty Capital, Inc. (SRC-PA) Income Statement Analysis – Financial Results
- Cheniere Energy, Inc. (LNG) Income Statement Analysis – Financial Results
- Nevada Zinc Corporation (GDSKF) Income Statement Analysis – Financial Results
- BW LPG Limited (BWLPG.OL) Income Statement Analysis – Financial Results
- Titan Mining Corporation (TIMCF) Income Statement Analysis – Financial Results
Poseida Therapeutics, Inc. (PSTX)
About Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 64.70M | 130.36M | 31.24K | 0.00 | 0.00 | 0.00 | 2.99M | 9.77M |
| Cost of Revenue | 156.77M | 5.17M | 4.55M | 2.59M | 1.19M | 689.00K | 0.00 | 0.00 |
| Gross Profit | -92.07M | 125.19M | -4.52M | -2.59M | -1.19M | -689.00K | 2.99M | 9.77M |
| Gross Profit Ratio | -142.29% | 96.03% | -14,472.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 156.77M | 152.90M | 136.73K | 103.52K | 60.39M | 30.88M | 19.10M | 9.86M |
| General & Administrative | 37.44M | 37.54M | 35.92K | 23.03K | 18.46M | 9.67M | 5.48M | 5.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -220.00K |
| SG&A | 37.44M | 37.54M | 35.92K | 23.03K | 18.46M | 9.67M | 5.48M | 5.13M |
| Other Expenses | 0.00 | 2.86M | 19.80K | 280.00 | 2.56M | -821.00K | 37.00K | 0.00 |
| Operating Expenses | 194.21M | 190.44M | 172.65K | 126.55K | 78.85M | 40.56M | 24.58M | 15.00M |
| Cost & Expenses | 179.35M | 190.44M | 172.65K | 126.55K | 78.85M | 40.56M | 24.58M | 15.22M |
| Interest Income | 0.00 | 6.37M | 3.36M | 3.51M | 1.55M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.67M | 6.37M | 3.36K | 3.51K | 3.55M | 1.80M | 558.00K | 0.00 |
| Depreciation & Amortization | 5.61M | 5.17M | 4.55M | 2.59M | 1.19M | 689.00K | 676.00K | 220.00K |
| EBITDA | -109.04M | -54.77M | -117.06M | -145.48M | -91.68M | -45.12M | -20.88M | -5.12M |
| EBITDA Ratio | -168.52% | -43.79% | -389.32% | 0.00% | 0.00% | 0.00% | -699.50% | -53.53% |
| Operating Income | -129.50M | -59.95M | -141.41K | -126.55K | -85.53M | -41.99M | -19.67M | -5.45M |
| Operating Income Ratio | -200.15% | -45.98% | -452.69% | 0.00% | 0.00% | 0.00% | -658.89% | -55.78% |
| Total Other Income/Expenses | 6.18M | -3.51M | 16.44M | -129.65M | -7.68M | -2.62M | 1.40M | 109.00K |
| Income Before Tax | -123.32M | -63.46M | -124.97K | -129.78K | -86.53M | -44.61M | -20.19M | -5.34M |
| Income Before Tax Ratio | -190.60% | -48.68% | -400.07% | 0.00% | 0.00% | 0.00% | -676.35% | -54.67% |
| Income Tax Expense | 107.00K | 544.00K | -4.53M | -2.58M | 6.11M | -202.00K | -527.00K | -765.00K |
| Net Income | -123.43M | -64.00M | 4.40M | 2.45M | -92.64M | -44.40M | -19.66M | -4.58M |
| Net Income Ratio | -190.76% | -49.10% | 14,097.81% | 0.00% | 0.00% | 0.00% | -658.69% | -46.84% |
| EPS | -1.37 | -0.89 | 0.07 | 0.07 | -2.33 | -1.24 | -0.49 | -0.08 |
| EPS Diluted | -1.37 | -0.89 | 0.07 | 0.07 | -2.33 | -1.24 | -0.49 | -0.08 |
| Weighted Avg Shares Out | 90.19M | 71.91M | 62.18M | 36.00M | 39.73M | 35.93M | 39.73M | 59.32M |
| Weighted Avg Shares Out (Dil) | 90.19M | 71.95M | 62.24M | 36.00M | 39.73M | 35.93M | 39.73M | 59.32M |
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTX
Poseida shares triple on Tuesday, boosted by Roche collaboration
Why This Gene-Therapy Company's Stock Is Rising 228%
Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
Source: https://incomestatements.info
Category: Stock Reports